Format

Send to

Choose Destination
J Subst Abuse Treat. 2014 Apr;46(4):456-62. doi: 10.1016/j.jsat.2013.10.014. Epub 2013 Nov 12.

Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients.

Author information

1
Health Analytics, LLC, 9200 Rumsey Road, Suite 215, Columbia, MD 21045, USA. Electronic address: joseph.tkacz@healthanalytic.com.
2
Institute of Addiction Medicine, 1000 Germantown Pike, Suite H2, Plymouth Meeting, PA 19462, USA.
3
Aetna Behavioral Health, 930 Harvest Drive, Mail Stop U32N, Blue Bell, PA 19422, USA.
4
Health Analytics, LLC, 9200 Rumsey Road, Suite 215, Columbia, MD 21045, USA.

Abstract

Buprenorphine-medication assisted therapy (B-MAT) is an effective treatment for opioid dependence, but may be considered cost-prohibitive based on ingredient cost alone. The purpose of this study was to use medical and pharmacy claims data to estimate the healthcare service utilization and costs associated with B-MAT adherence among a sample of opioid dependent members. Members were placed into two adherence groups based on 1-year medication possession ratio (≥ 0.80 vs. <0.80). The B-MAT adherent group incurred significantly higher pharmacy charges (adjusted means; $6,156 vs. $3,581), but lower outpatient ($9,288 vs. $14,570), inpatient ($10,982 vs. $26,470), ER ($1,891 vs. $4,439), and total healthcare charges ($28,458 vs. $49,051; p<0.01) compared to non-adherent members. Adherence effects were confirmed in general linear models. Though B-MAT adherence requires increased pharmacy utilization, adherent individuals were shown to use fewer expensive health care services, resulting in overall reduced healthcare expenditure compared to non-adherent patients.

KEYWORDS:

Adherence; Buprenorphine; Dependence; Opiate; Opioid; Pharmacoeconomics

PMID:
24332511
DOI:
10.1016/j.jsat.2013.10.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center